STAAR Surgical Company (STAA) was Upgraded by The Benchmark Company to ” Buy” and the brokerage firm has set the Price Target at $6. Earlier the firm had a rating of “Hold ” on the company shares. The Benchmark Company advised their investors in a research report released on May 18, 2016.
On the company’s financial health, STAAR Surgical Company reported $-0.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 11, 2016. Analyst had a consensus of $0.02. The company had revenue of $19.30 million for the quarter, compared to analysts expectations of $19.60 million. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
STAAR Surgical Company closed down -0.3 points or -5.54% at $5.12 with 5,13,277 shares getting traded on Monday. Post opening the session at $5.42, the shares hit an intraday low of $4.98 and an intraday high of $5.55 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Aug 26, 2015, Caren L Mason (CEO) purchased 10,000 shares at $7.34 per share price. According to the SEC, on Aug 11, 2015, Lou Silverman (director) purchased 1,500 shares at $8.18 per share price. On Aug 7, 2015, Jack Steven Roush (director) purchased 1,000 shares at $8.08 per share price, according to the Form-4 filing with the securities and exchange commission.
STAAR Surgical Company designs develops manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company’s principal products are intraocular lenses (IOLs) and implantable Collamer lenses (ICLs). IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts and include the Company’s lines of silicone and Collamer IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). ICLs consisting of the Company’s ICL and Toric implantable collamer lenses (TICL) are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness) hyperopia (far-sightedness) and astigmatism. The Company operates under the brands STAAR Visian Collamer CentraFLOW AquaPORT nanoFLEX nanoPOINT Epiphany and AquaFlow. Collamer is the brand name for its collagen copolymer lens material.